An additional analysis of the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, which investigated the suppressive effect of the SGLT2 inhibitor canagliflozin on the onset of cardiovascular events in patients with type 2 diabetes, examined its suppressive effect on renal events [17]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.